Abbott Diabetes Care, Inc.: FDA filings under this applicant name

FDA lists 39 510(k) clearances under 2 spellings of the applicant name “Abbott Diabetes Care, Inc.” (first 2000, latest 2024), plus 2 PMA and 1 De Novo decisions, across 10 product codes in 1 review panel. Median 510(k) review time under this name: 164 days. Since 2017 the median was 178 days, against 191 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.

Caduvo groups this applicant name under Abbott, based on public ownership records.

510(k) clearances per year

YearClearancesMedian review days
2012131
20132151
20141228
20151356
2016192
2017191
20180—
20190—
20201190
20213237
20222240
20233150
20242178
20250—
20260—

Review time against the same product codes

Since 2017, 510(k)s cleared under the name Abbott Diabetes Care, Inc. took a median 178 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 191 days.

Top product codes

Product codeDeviceSubmissions510(k) clearances
NBWSystem, Test, Blood Glucose, Over The Counter1919
QLGIntegrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems77
LFRGlucose Dehydrogenase, Glucose55
LZGPump, Infusion, Insulin33
QBJIntegrated Continuous Glucose Monitoring System, Factory Calibrated33
JINNitroprusside, Ketones (Urinary, Non-Quant.)11
MDSSensor, Glucose, Invasive10
PZESensor, Glucose, Invasive, Non-Adjunctive, Factory-Calibrated, User-Initiated10
SBHIntegrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter11
SJDIntegrated Continuous Glucose Ketone Monitoring System10

Review panels

Most recent Abbott Diabetes Care, Inc. 510(k) clearances

510(k)DeviceProduct codeDecision dateReview days
K233861Libre Rio Continuous Glucose Monitoring SystemSBH2024-06-07184
K233537FreeStyle Libre 3 Continuous Glucose Monitoring System; FreeStyle Libre 2 Flash Glucose Monitoring SystemQBJ2024-04-23172
K223435FreeStyle Libre 3 Continuous Glucose Monitoring System; FreeStyle Libre 2 Flash Glucose Monitoring SystemQBJ2023-04-13150
K222447FreeStyle Libre 2 Flash Glucose Monitoring System; Freestyle Libre 3 Continuous Glucose Monitoring SystemQBJ2023-03-03200
K223537FreeStyle Libre 2 System, FreeStyle Libre 3 SystemQLG2023-02-2190
K213996FreeStyle Libre 3 Continuous Glucose Monitoring SystemQLG2022-05-26157
K212132FreeStyle Libre 3 Continuous Glucose Monitoring SystemQLG2022-05-26322
K210943FreeStyle Libre 2 Flash Glucose Monitoring System (with FreeStyle Libre 2 App)QLG2021-11-22237
K211102FreeStyle Libre 2 Flash Glucose Monitoring SystemQLG2021-08-11120
K201761FreeStyle Libre 2 Flash Glucose Monitoring System (with FreeStyle Libre 2 App)QLG2021-07-30396

29 earlier clearances. See the full list in Caduvo.

PMA and De Novo decisions

NumberPathwayDeviceDecision date
DEN250049De NovoIntegrated Continuous Glucose Ketone Monitoring System2026-08-25
P160030PMAFreestyle Libre Flash Glucose Monitoring System2017-09-27
P150021PMAFREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM2016-09-23

Recalls

57 product recalls in 21 recall events; 10 initiated in the last five years. Most recent: 2025-11-24.

2 product recalls in 1 recall event filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 0 initiated in the last five years. Most often: Cardinal Health Inc. (2).

These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.

Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.

Device clinical trials

An industry sponsor named Abbott Diabetes Care, Inc. is the lead sponsor of 42 device studies on ClinicalTrials.gov (5 active or recruiting). Most recent:

Parent company SEC filings

ABBOTT LABORATORIES (ABT): EDGAR filings, CIK 1800. Caduvo groups Abbott Diabetes Care, Inc. under Abbott; the parent's SEC registrant is entered by hand for the group, not matched by name.

Related HCPCS codes

HCPCS Level II codes whose descriptors match the device names of the product codes filed under Abbott Diabetes Care, Inc. (a text match, not an official crosswalk):

FDA spellings included

FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:

Other FDA applicant names starting with the same word

FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.

Frequently asked questions

How many FDA 510(k) clearances are listed under Abbott Diabetes Care, Inc.?

FDA lists 39 510(k) clearances under 2 spellings of the applicant name “Abbott Diabetes Care, Inc.” (first 2000, latest 2024), plus 2 PMA and 1 De Novo decisions, across 10 product codes in 1 review panel. Filings under other applicant names, such as subsidiaries, are not included.

How long has FDA taken to clear 510(k)s filed by Abbott Diabetes Care, Inc.?

The median time from FDA receipt to decision across 510(k)s cleared under the name Abbott Diabetes Care, Inc. is 164 days. Since 2017: 178 days, versus 191 days for all cleared 510(k)s in the same product codes.

Which FDA product codes appear under Abbott Diabetes Care, Inc.?

The most frequent FDA product codes under this applicant name are NBW (System, Test, Blood Glucose, Over The Counter, 19); QLG (Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems, 7); LFR (Glucose Dehydrogenase, Glucose, 5).

Next steps

Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.

All FDA device companies · FDA product code lookup